Antiarrhythmic Potential of Anticytokine Therapy in Rheumatoid Arthritis: Tocilizumab Reduces Corrected QT Interval by Controlling Systemic Inflammation

Publisher： John Wiley & Sons Inc

E-ISSN： 2151-4658|67|3|332-339

ISSN： 2151-464x

Source： ARTHRITIS CARE AND RESEARCH, Vol.67, Iss.3, 2015-03, pp. : 332-339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 18, Iss. 1, 2015-01 ,pp. : 108-110

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brief Report: Leucine‐Rich α2‐Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti–Interleukin‐6 Biologic Therapy in Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 8, 2015-05 ,pp. : 2056-2060

John Wiley & Sons Inc

Access to resources Recommend Favorite

Catch‐Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 3, 2015-03 ,pp. : 840-848

John Wiley & Sons Inc

Access to resources Recommend Favorite

Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?

By Martinović Kaliterna Dušanka   Aljinović Jure   Perković Dijana   Marasović Krstulović Daniela   Marinović Ivanka   Vlak Tonko  

Wiener klinische Wochenschrift, Vol. 126, Iss. 3-4, 2014-02 ,pp. : 126-129

Springer Publishing Company

Access to resources Recommend Favorite

Angiotensin II in inflammation, immunity and rheumatoid arthritis

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 179, Iss. 2, 2015-02 ,pp. : 137-145

John Wiley & Sons Inc

Access to resources Recommend Favorite